Reuters -- Novartis AG expects to file for two new approvals of cancer drugs, including big hope Tasigna, by the end of the month and has several more on the way to further boost its lucrative portfolio.
Reuters -- Novartis AG expects to file for two new approvals of cancer drugs, including big hope Tasigna, by the end of the month and has several more on the way to further boost its lucrative portfolio.
